文献速递神经肿瘤

多参数MR-PET在高代谢区域测量反映初治弥漫性胶质瘤分子状态与分级的差异

Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
PubMed 文献 · J Neurooncol · 2020-09-14

结果显示FDOPAROI提取的nSUVmax、rCBV、ADC及体积在IDH野生型与突变型、高级别与低级别胶质瘤间存在显著差异,且FDOPAROI对分子状态和分级的判别准确率高于FLAIRROI。

要点

  • FDOPAROI的nSUVmax和rCBV在IDH野生型及高级别胶质瘤中显著更高,ADC更低。
  • FDOPAROI体积在1p19q共缺失及高级别胶质瘤中显著更高。
  • FDOPAROI提取的影像指标判别分子状态和分级的AUC高于FLAIRROI。

核心结论

  • FDOPA高代谢ROI可提取有用的胶质瘤影像特征,有助于揭示不同分子状态或肿瘤分级间的生物学差异。

主要发现

  • 使用FLAIRROI或FDOPAROI时,IDH野生型较突变型、高级别较低级别胶质瘤的nSUVmax和rCBV显著更高,ADC更低。
  • FDOPAROI体积在1p19q共缺失较非共缺失、高级别较低级别胶质瘤中显著更高。
  • FDOPAROI提取的影像指标判别分子状态和分级的AUC高于FLAIRROI(IDH状态0.87 vs. 0.82;1p19q状态0.78 vs. 0.73;分级0.87 vs. 0.76),但差异未达显著。

临床怎么用

  • 可利用FDOPA PET高代谢区域提取多参数影像特征,辅助无创评估胶质瘤的IDH状态、1p19q状态及分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess whether hypermetabolically-defined regions of interest (ROIs) on 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) could be used to evaluate physiological features and whether there are measurable differences between molecular subtypes and tumor grades. METHODS: Sixty-eight treatment-naïve glioma patients who underwent FDOPA PET and magnetic resonance imaging (MRI) were retrospectively included. Fluid-attenuated inversion recovery hyperintense regions (FLAIRROI) were segmented. FDOPA hypermetabolic regions (FDOPAROI, tumor-to-striatum ratios > 1) within FLAIRROI were extracted. Normalized maximum standardized uptake value (nSUVmax), volume of each ROI, and median relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) within FLAIRROI or FDOPAROI were calculated. Imaging metrics were compared using Students t or Mann-Whitney U tests. Area under the curve (AUC) of receiver-operating characteristic curves were used to determine whether imaging metrics within FLAIRROI or FDOPAROI can discriminate different molecular statuses or grades. RESULTS: Using either FLAIRROI or FDOPAROI, the nSUVmax and rCBV were significantly higher and the ADC was lower in isocitrate dehydrogenase (IDH) wild-type than mutant gliomas, and in higher-grade gliomas (HGGs) than lower-grade gliomas (LGGs). The FDOPAROI volume was significantly higher in 1p19q codeleted than non-codeleted gliomas, and in HGGs than LGGs. Although not significant, imaging metrics extracted by FDOPAROI discriminated molecular status and tumor grade more accurately than those extracted by FLAIRROI (AUC of IDH status, 0.87 vs. 0.82; 1p19q status, 0.78 vs. 0.73; grade, 0.87 vs. 0.76). CONCLUSION: FDOPA hypermetabolic ROI may extract useful imaging features of gliomas, which can illuminate biological differences between different molecular status or tumor grades.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tatekawa H, Hagiwara A, Uetani H, et al. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. J Neurooncol. 2020. PMID: 32929644. doi:10.1007/s11060-020-03613-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。